Screening population:
3,839,791

Distributor:
MPG d.o.o Beograd
Appointed 2020

Cervical cancer is the 4th most common female cancer in Montenegro, and the second most frequent cancer among women between 15 and 44 year of age.

Screening population:
4,197,298

Distributor:
Gorton Health Service Pty Ltd
Appointed 2019

Cervical cancer is the 2nd most common cancer for women in Cambodia.

Screening population:
13,000,000

Distributor:
IMS
Appointed 2025

Sales to Kazakhstan, Belarus, Kyrgyzstan and Armenia, to both private and public health systems are to follow product registration, supported by TruScreen’s inclusion in the Russian Obstetricians and Gynaecologists guideline in early 2025. This is a key reference guide for all former Soviet republics.

Screening population:
402,269,064

Distributor:
Siweixiangtai Tech Ltd Co.
Appointed 2014

China is TruScreen’s most established market. It accounts for over 20% of cervical cancer diagnoses worldwide. TruScreen has been involved in several large-scale evaluation trials with public governing bodies, screening over 18,000 women.

Screening population:
390,884

TruScreen plans to supply Public Screening Program directly in FY26.

Screening population:
4,660,000

Distributor:
Renovate Biologicals Pvt Ltd
Appointed 2025

Cervical cancer is the second most common cancer among women in India, despite being the fourth most common globally. One woman dies from cervical cancer every eight minutes in the country, making it a significant public health concern. In 2023 it was estimated that 123,907 women were diagnosed with cervical cancer and 77,348 died.

Screening population:
68,377,584

Distributor:
PT Mawar Mitra Medika
Appointed 2025

Cervical cancer ranks as the 2nd most frequent cancer among women in Indonesia. In 2018 TruScreen was granted approval, by Department Kesehatan RI, for use and sale in the country.

Screening population:
3,409,164

Distributor:
Sadaf Medical Supplies

In United Arab Emirates, cervical cancer ranks as the 5th most frequent cancer among women and the 3rd most frequent cancer among women between 15 and 44 years of age.

In Jordan, cervical cancer ranks as the 11th most frequent cancer among women and the 10th most frequent cancer among women between 15 and 44 years of age.

Screening population:
655,658

Distributor:
Renovate Biologicals
Appointed 2025

Cervical cancer is the 3rd most common cancer in women aged 15 to 44 years in Kuwait.

Screening population:
8,023,056

Distributor:
Intega Pte Ltd
Appointed 2024

Cervical cancer is the 2nd most frequent cancer for women aged between 15 and 44 years in Malaysia, and the 3rd most common cancer for women overall in the country.

Screening population:
52,271,615

Distributor:
Sunbird S.A. de C.V.
Appointed 2020

Mexico is TruScreen’s entry point into South America, with cervical cancer being the third most common cancer in women in the region. TruScreen has been present in Mexico since 2015. Sunbird is also working with authorities in Panama, Equador and Bolivia to identify opportunities.

Screening population:
4,179,844

Distributor:
Sadaf Medical Supplies

Cervical cancer ranks as the 2nd most frequent cancer among women in Rwanda and the most frequent cancer among women between 15 and 44 years of age.

Screening population:
7,582,946

Distributor:
Bettalife Trading FZC
Appointed 2018

Cervical cancer ranks as the 9th most frequent cancer among women in Saudi Arabia. More than 40% of cervical cancer cases are diagnosed at advanced stages due the absence of a routine cervical screening program.

Screening population:
2,126,799

Distributor:
Intega Pte Ltd
Appointed 2024

Cervical cancer is the 11th most frequent cancer for women aged between 15 and 44 years in Singapore, and the 5th most common cancer for women overall in the country.

Screening population:
19,947,839

Distributor:
Air
Appointed 2025

Cervical cancer is the 2nd most frequent cancer for women aged between 15 and 44 years in South Africa, and the most common cancer for women overall in the country.

Screening population:
19,947,839

Distributor:
Future Care

Cervical cancer is the 2nd most frequent cancer for women aged between 15 and 44 years in Sri Lanka, and the 4th most common cancer for women overall in the country.

Screening population:
20,650,154

Distributor:
Intega Pte Ltd
Appointed 2024

Cervical cancer is 2nd most prevalent cancer for women in Thailand.

Screening population:
2,353,750

Distributor:
Sadaf Medical Supplies

In United Arab Emirates, cervical cancer ranks as the 5th most frequent cancer among women and the 3rd most frequent cancer among women between 15 and 44 years of age.

Screening population:
11,617,411

Cervical cancer ranks as the 2nd most common cancer for women in Uzbekistan, and 2nd most frequent cancer among women between 15 and 44 years of age. TruScreen is working directly with the Uzbek Ministry of Health to launch a 500 patient pilot screening program to commence in October 2025 in Karakalpakstan, Uzbekistan, with planned province by province expansion.

Screening population:
35,887,201

Distributor:
Gorton Health Services (GHS)
Appointed 2016

Cervical cancer ranks as the 7th most common cancer for women in Vietnam. In 2020, TruScreen received Ministry of Health approval for use in leading Hanoi Obstetrics and Gynaecology Hospital. In July 2025, a 260,000 patient Public Screening Program launched in Ho Chin Minh City.

Screening population:
2,698,797

Distributor:
Southern Skies Medical Pty Ltd
Appointed 2018

Cervical cancer is the most common cancer among women in Zimbabwe. In 2018 TruScreen partnered with Zimbabwe’s National Aids Council (NAC) for a national cervical screening project.